ESMO Advanced Course on Precision Oncology Across Tumours: Tumour-agnostic and Tumour-modulated

Programme
ESMO ADVANCED COURSE PROGRAMME
PRECISION ONCOLOGY ACROSS TUMOURS:
TUMOUR-AGNOSTIC AND TUMOUR-MODULATED
(MSI and TMB, NTRK, BRAF, HRD)
Lisbon, Portugal
5-6 May 2023

CO-CHAIRS
Pilar Garrido López, Spain
Nikolas von Bubnoff, Germany

SPEAKERS
Benjamin Besse, France
Tilman Brummer, Germany
Hauke Busch, Germany
Ilaria Colombo, Switzerland
Liza Hendriks, Netherlands
Fernando López-Ríos, Spain

LEARNING OBJECTIVES

• To understand the biology of MSI/HRD, TMB, NTRK and BRAF and the frequency of these biomarkers across entities
• To learn the diagnostic tools, the clinical significance of specific variants and specify the actionability and level of evidence with regard to personalized treatment recommendations

ACCREDITATION

The programme of this event has been accredited with 7 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
**Friday, 5 May 2023**

09:00-09:10  **Welcome and introduction**

10’  Welcome and Learning Objectives Introduction  
Pilar Garrido López, ES and Nikolas von Bubnoff, DE

09:10-10:30  **Session 1 – Molecular target / Family of targets – MSI and TMB**  
Chair: Nikolas von Bubnoff, DE

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)  
Hauke Busch, DE

5’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Lizza Hendriks, NL

5’  Q&A

15’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Hauke Busch, DE

5’  Q&A

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board  
Lizza Hendriks, NL

5’  Q&A

10:30-11:00  **Coffee break**

11:00-12:35  **Session 2 – Molecular target / Family of targets – NTRK**  
Chairs: Pilar Garrido López, ES and Fernando López-Rios, ES

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)  
Fernando López-Rios, ES

5’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Pilar Garrido López, ES

5’  Q&A

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Fernando López-Rios, ES

10’  Q&A

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board  
Nikolas von Bubnoff, DE

10’  Q&A

12:35-13:35  **Lunch**
13:35-15:10  Session 3 – Molecular target / Family of targets – BRAF  
Chairs: Tilman Brummer, DE and Nikolas von Bubnoff, DE

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)  
Tilman Brummer, DE

5’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Benjamin Besse, FR

5’  Q&A

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Tilman Brummer, DE

10’  Q&A

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board  
Nikolas von Bubnoff, DE

10’  Q&A

15:10-15:40  Coffee break

19:30  Networking Dinner

Saturday, 6 May 2023

09:00-11:50  Session 4 – Molecular target / Family of targets – HRD  
Chairs: Pilar Garrido López, ES and Nikolas von Bubnoff, DE

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)  
Hauke Busch, DE

15’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Ilaria Colombo, CH

15’  Q&A

10:00-10:30  Coffee break

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Hauke Busch, DE

20’  Q&A

30’  Value / health economics of testing  
Fernando López-Ríos, ES

10’  Q&A

11:50-12:00  Synthesis and wrap-up

12:00-13:00  Lunch